eculizumab NMOSD
Selected indexed studies
- Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. (Mult Scler, 2022) [PMID:34498507]
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. (Neurol Neuroimmunol Neuroinflamm, 2023) [PMID:37258412]
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (J Neurol, 2024) [PMID:37676297]
_Worker-drafted node — pending editorial review._
Connections
eculizumab NMOSD is a side effect of
Sources
- International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. (2023) pubmed
- Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2023) pubmed
- Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension. (2022) pubmed
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. (2024) pubmed
- Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. (2023) pubmed
- Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2019) pubmed
- Eculizumab in AQP4-IgG NMOSD: Efficacy in the Real World and Potential Warning of Meningococcal Vaccines. (2024) pubmed
- Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. (2021) pubmed
- Myelin-oligodendrocyte glycoprotein antibody-associated disease. (2021) pubmed
- Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. (2021) pubmed